Detalhe da pesquisa
1.
Efficacy and safety of switching to dolutegravir/lamivudine in virologically suppressed people with HIV-1 aged ≥ 50 years: week 48 pooled results from the TANGO and SALSA studies.
AIDS Res Ther
; 21(1): 17, 2024 Mar 21.
Artigo
Inglês
| MEDLINE | ID: mdl-38515183
2.
Efficacy and Safety of Switching to the 2-Drug Regimen Dolutegravir/Lamivudine Versus Continuing a 3- or 4-Drug Regimen for Maintaining Virologic Suppression in Adults Living With Human Immunodeficiency Virus 1 (HIV-1): Week 48 Results From the Phase 3, Noninferiority SALSA Randomized Trial.
Clin Infect Dis
; 76(4): 720-729, 2023 02 18.
Artigo
Inglês
| MEDLINE | ID: mdl-35235656
3.
Pharmacokinetic and pharmacokinetic/pharmacodynamic characterization of the dolutegravir/rilpivirine two-drug regimen in SWORD-1/-2 phase 3 studies.
Br J Clin Pharmacol
; 89(7): 2190-2200, 2023 07.
Artigo
Inglês
| MEDLINE | ID: mdl-36740580
4.
Efficacy and Safety of Switching to Dolutegravir/Lamivudine Versus Continuing a Tenofovir Alafenamide-Based 3- or 4-Drug Regimen for Maintenance of Virologic Suppression in Adults Living With Human Immunodeficiency Virus Type 1: Results Through Week 144 From the Phase 3, Noninferiority TANGO Randomized Trial.
Clin Infect Dis
; 75(6): 975-986, 2022 09 29.
Artigo
Inglês
| MEDLINE | ID: mdl-35079789
5.
Integrase Inhibitor Resistance Mechanisms and Structural Characteristics in Antiretroviral Therapy-Experienced, Integrase Inhibitor-Naive Adults with HIV-1 Infection Treated with Dolutegravir plus Two Nucleoside Reverse Transcriptase Inhibitors in the DAWNING Study.
Antimicrob Agents Chemother
; 66(1): e0164321, 2022 01 18.
Artigo
Inglês
| MEDLINE | ID: mdl-34694877
6.
Efficacy and Safety of Switching to Dolutegravir/Lamivudine Fixed-Dose 2-Drug Regimen vs Continuing a Tenofovir Alafenamide-Based 3- or 4-Drug Regimen for Maintenance of Virologic Suppression in Adults Living With Human Immunodeficiency Virus Type 1: Phase 3, Randomized, Noninferiority TANGO Study.
Clin Infect Dis
; 71(8): 1920-1929, 2020 11 05.
Artigo
Inglês
| MEDLINE | ID: mdl-31905383
7.
Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials.
Lancet
; 393(10167): 143-155, 2019 01 12.
Artigo
Inglês
| MEDLINE | ID: mdl-30420123
8.
Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: phase 3, randomised, non-inferiority SWORD-1 and SWORD-2 studies.
Lancet
; 391(10123): 839-849, 2018 03 03.
Artigo
Inglês
| MEDLINE | ID: mdl-29310899
9.
Correction for Underwood et al., "Integrase Inhibitor Resistance Mechanisms and Structural Characteristics in Antiretroviral Therapy-Experienced, Integrase Inhibitor-Naive Adults with HIV-1 Infection Treated with Dolutegravir plus Two Nucleoside Reverse Transcriptase Inhibitors in the DAWNING Study".
Antimicrob Agents Chemother
; 67(3): e0032622, 2023 Mar 16.
Artigo
Inglês
| MEDLINE | ID: mdl-36794938
10.
Bioequivalence of a Fixed-Dose Combination Tablet of the Complete Two-Drug Regimen of Dolutegravir and Rilpivirine for Treatment of HIV-1 Infection.
Antimicrob Agents Chemother
; 62(9)2018 09.
Artigo
Inglês
| MEDLINE | ID: mdl-29987139
11.
Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection.
N Engl J Med
; 369(19): 1807-18, 2013 Nov 07.
Artigo
Inglês
| MEDLINE | ID: mdl-24195548
12.
No clinically significant pharmacokinetic interactions between dolutegravir and daclatasvir in healthy adult subjects.
BMC Infect Dis
; 16: 347, 2016 07 22.
Artigo
Inglês
| MEDLINE | ID: mdl-27450277
13.
Effect of carbamazepine on dolutegravir pharmacokinetics and dosing recommendation.
Eur J Clin Pharmacol
; 72(6): 665-70, 2016 Jun.
Artigo
Inglês
| MEDLINE | ID: mdl-26898568
14.
Effects of boceprevir and telaprevir on the pharmacokinetics of dolutegravir.
Br J Clin Pharmacol
; 78(5): 1043-9, 2014 Nov.
Artigo
Inglês
| MEDLINE | ID: mdl-24838177
15.
Pharmacokinetics of dolutegravir in HIV-seronegative subjects with severe renal impairment.
Eur J Clin Pharmacol
; 70(1): 29-35, 2014 Jan.
Artigo
Inglês
| MEDLINE | ID: mdl-24096683
16.
Genetic fallout in biocultural landscapes: molecular imperialism and the cultural politics of (not) seeing transgenes in Mexico.
Soc Stud Sci
; 44(6): 901-29, 2014 Dec.
Artigo
Inglês
| MEDLINE | ID: mdl-25608443
17.
Efficacy and Safety of Switching to Dolutegravir/Lamivudine Versus Continuing a Tenofovir Alafenamide-Based Regimen in Virologically Suppressed Adults With Human Immunodeficiency Virus Type 1: Subgroup Analysis of Participants With Elvitegravir as Baseline Third Agent From the TANGO Study.
Open Forum Infect Dis
; 11(5): ofae227, 2024 May.
Artigo
Inglês
| MEDLINE | ID: mdl-38737429
18.
Dolutegravir + Lamivudine vs. Dolutegravir + Tenofovir Disoproxil Fumarate/Emtricitabine: Very-Low-Level HIV-1 Replication through 144 Weeks in the GEMINI-1 and GEMINI-2 Studies.
Viruses
; 16(3)2024 Mar 06.
Artigo
Inglês
| MEDLINE | ID: mdl-38543770
19.
Durable Efficacy of Switching From a 3- or 4-Drug Tenofovir Alafenamide-Based Regimen to the 2-Drug Regimen Dolutegravir/Lamivudine in the TANGO Study Through Week 196.
J Acquir Immune Defic Syndr
; 2024 Mar 01.
Artigo
Inglês
| MEDLINE | ID: mdl-38346427
20.
Very-Low-Level Viremia, Inflammatory Biomarkers, and Associated Baseline Variables: Three-Year Results of the Randomized TANGO Study.
Open Forum Infect Dis
; 11(1): ofad626, 2024 Jan.
Artigo
Inglês
| MEDLINE | ID: mdl-38213637